Featured Articles

The U.S. Food and Drug Administration has approved an expanded indication for Tzield (teplizumab-mzwv), allowing its use in children as young as one year old to delay the onset of stage…
Read More...

Boehringer Ingelheim has announced a major expansion of its global Computational Innovation network with the launch of a new artificial intelligence (AI) and machine learning (ML)…
Read More...

Boehringer Ingelheim and Zai Lab have announced a new clinical collaboration aimed at advancing a novel dual-targeting strategy for difficult-to-treat cancers. The partnership will…
Read More...

Daiichi Sankyo and Merck & Co. (known as MSD outside the United States and Canada) have announced that the U.S. Food and Drug Administration has accepted and granted Priority Review…
Read More...

Novo Nordisk has announced a strategic partnership with OpenAI aimed at transforming healthcare through advanced artificial intelligence, with a focus on accelerating drug discovery and…
Read More...

Gilead Sciences, Inc. has announced a definitive agreement to acquire Tubulis GmbH, a clinical-stage biotech firm specializing in next-generation antibody-drug conjugates (ADCs). The…
Read More...

Eli Lilly and Company has announced a definitive agreement to acquire Centessa Pharmaceuticals in a transaction valued at approximately $6.3 billion upfront, with additional…
Read More...

Teva Pharmaceutical Industries has announced a series of significant milestones in its biosimilars portfolio, underscoring progress in its broader “Pivot to Growth” strategy and…
Read More...

Biogen Inc. has announced a definitive agreement to acquire Apellis Pharmaceuticals in a deal valued at approximately $5.6 billion, marking a significant step in Biogen’s strategy to…
Read More...

Merck & Co.—known as MSD outside North America—has announced a definitive agreement to acquire Terns Pharmaceuticals in a deal valued at approximately $6.7 billion, strengthening…
Read More...

UCB has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), recommending an update to the marketing authorization for…
Read More...

Gilead Sciences has announced a definitive agreement to acquire Ouro Medicines, a privately held firm focused on developing T cell engager therapies for autoimmune diseases. The move…
Read More...

Novartis has announced a strategic agreement with Synnovation Therapeutics, LLC to acquire SNV4818, an investigational oral therapy designed to treat hormone receptor-positive,…
Read More...

Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has approved ICOTYDE™ (icotrokinra), a novel oral therapy for the treatment of moderate-to-severe…
Read More...

Voro Therapeutics has entered into a research collaboration with Daiichi Sankyo to develop next-generation antibody-drug conjugates (ADCs) using its proprietary PrimeBody platform. The…
Read More...

Roche has announced a major expansion of its global artificial intelligence (AI) infrastructure, unveiling a large-scale “AI factory” powered by next-generation accelerated computing…
Read More...

Johnson & Johnson has received approval from the U.S. Food and Drug Administration for its TECNIS PureSee intraocular lens (IOL), a new extended depth of focus (EDOF) lens designed…
Read More...

Danish pharmaceutical company Novo Nordisk has announced a new agreement with telehealth platform Hims & Hers Health aimed at expanding patient access to its FDA-approved…
Read More...

GSK plc has entered into a licensing agreement with Alfasigma S.p.A. granting the Italian pharmaceutical company exclusive global rights to develop, manufacture, and commercialize…
Read More...

Pharmaceutical company GSK plc has entered into a licensing agreement with Italian drugmaker Alfasigma S.p.A. granting the latter worldwide exclusive rights to develop, manufacture and…
Read More...